Number of NDA of innovative drugs approved in China 2018-2021

In 2021, the Center for Drug Evaluation of the National Medical Products Administration (NMPA) in China approved 69 New Drug Applications (NDA) for innovative drugs, with more than half of all approvals granted to chemical drugs. A New Drug Application (NDA) is the mechanism through which pharmaceutical manufacturers propose that the regulatory body approve a new drug or biopharmaceutical for general use and sale.

于2021年，中国国家药品监督管理局（NMPA）批准了69项创新药物的新药申请（NDA），其中超过半数批准为化学药物。新药申请（NDA）是制药企业向监管机构提议批准新药或生物制药以供广泛使用和销售的一种机制。